Search

… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas …

… QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the Company’s second …

… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNA Editing Summit During the 1 st RNA Editing Summit to be held …

… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … advisory board. "Dr. Yu is a pioneer of targeted RNA editing to correct protein translation defects caused by …

… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position with $50 …

… into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected by …

… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas …

… and other DEB mutations An introduction to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the …

… ProQR’s strategic focus on its proprietary Axiomer ®  RNA editing technology platform and continued advancement of …

… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … to progress its other pipeline candidates, to advance its RNA-editing technology platforms, and for working capital and …